Nuvectis Pharma (NVCT) Common Equity (2021 - 2026)

Nuvectis Pharma has reported Common Equity for 6 years, with the latest figure at $14.2 million in Q1 2026.

• Quarterly Common Equity fell 32.14% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (down 32.14% YoY) and the FY2025 annual result came in at $18.4 million, up 89.57% from the prior year.
• Common Equity fell to $14.2 million in Q1 2026 per NVCT's latest filing, from $18.4 million in the prior quarter.
• Over five years, Common Equity peaked at $24.0 million in Q3 2025 and troughed at $9.7 million in Q4 2024.
• A 5-year average of $15.5 million and a median of $14.2 million in 2026 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity jumped 361.36% in 2022, then tumbled 38.38% in 2024.
• Over 5 years, Common Equity stood at $14.2 million in 2022, then decreased by 14.19% to $12.2 million in 2023, then slipped by 20.39% to $9.7 million in 2024, then surged by 89.57% to $18.4 million in 2025, then decreased by 22.77% to $14.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $14.2 million, $18.4 million, and $24.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.